PlanMySupps
Personalized, evidence-based supplement plans and infrastructure for supplement protocols.
Website: https://planmysupps.com/
Cover Block
| Attribute | Details |
|---|---|
| Company | PlanMySupps |
| Tagline | Personalized, evidence-based supplement plans and infrastructure for supplement protocols. [PlanMySupps, retrieved 2024] |
| Headquarters | Paris, France |
| Founded | 2021 |
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Solo founder |
| Funding Label | Pre-Seed |
Links
- Website: https://planmysupps.com/
- LinkedIn: https://www.linkedin.com/in/jessicalytle/
PlanMySupps maintains a minimal public footprint. The company website is the primary source for product information, while the LinkedIn profile of co-founder Jess Lytle provides the most detailed public view of the founding team and the company's positioning.
PlanMySupps is a Paris-based healthtech startup building software to generate personalized supplement protocols, a proposition that stands out for its explicit grounding in clinical evidence rather than wellness marketing. Founded in 2021 by Jess Lytle, the company positions its product as infrastructure for evidence-based supplement plans, a wedge into a market often characterized by generic recommendations [PlanMySupps, retrieved 2024]. The founding team's backgrounds in nutritional epidemiology and supplement coaching provide a credible foundation for the product's scientific positioning [LinkedIn, retrieved 2024] [RocketReach, retrieved 2024]. As of 2025, the company shows no public record of institutional funding, named enterprise customers, or major media coverage, indicating a very early, likely bootstrapped stage [Perplexity Sonar Pro Brief, retrieved 2024]. The next 12 to 18 months will be critical for demonstrating whether the evidence-based protocol engine can secure initial paying customers and forge the data partnerships necessary to validate its technical claims.
Data Accuracy: YELLOW -- Core product claims from company site; team backgrounds from professional profiles; absence of funding/customers corroborated by search.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Solo founder |
How the Company Got Here
PlanMySupps was founded in 2021 in Paris, France, as a remote-first healthtech venture [Crunchbase, 2026]. The company’s public identity is anchored by its founder, Jess Lytle, who has structured the business around a direct-to-consumer software model rather than supplement retail [PlanMySupps, 2024].
The company’s primary public milestone remains the launch of its website and product concept, which describes a protocol-generation engine for personalized supplement plans [PlanMySupps, 2024]. There is no public record of institutional funding rounds, major customer announcements, or partnership disclosures as of 2024-2025 [Perplexity Sonar Pro Brief, retrieved 2024].
The founding team’s academic and professional backgrounds provide the core narrative for the company’s evidence-based positioning. Jess Lytle holds an MSc in Nutritional Epidemiology from Harvard, a credential directly cited in the product’s framing [LinkedIn, 2024]. Cristina Gall, identified as CEO, is a Harvard-trained supplement coach, bringing practical experience from prior coaching work [Supplement Coaching, 2026] [RocketReach, retrieved 2024].
Data Accuracy: YELLOW -- Company founding details are confirmed via Crunchbase and founder profiles; operational milestones and entity structure are not publicly documented.
Product and Technology
The product is a software layer for supplement decision-making, not a direct seller of pills. According to its website, PlanMySupps provides personalized, evidence-based supplement plans and the infrastructure for building those protocols [PlanMySupps, retrieved 2024]. The language frames the service as a protocol-generation engine, a data and decision layer that sits between a user and the supplements they might purchase elsewhere.
Its differentiation hinges on the application of nutritional epidemiology to filter recommendations. The company's public positioning repeatedly emphasizes an evidence-based methodology, a claim anchored by co-founder Jess Lytle's academic background in nutritional epidemiology from Harvard [LinkedIn, retrieved 2024]. The product appears to generate individualized regimens by taking user inputs and structuring them against a database of clinical evidence, though the specific algorithms, data sources, and validation processes are not documented on the public site [Perplexity Sonar Pro Brief, retrieved 2024].
As a direct-to-consumer software product, the current user experience is consumer-facing. The website is pitched to individuals seeking a scientifically-grounded supplement plan, with no visible B2B pricing, provider dashboards, or language targeting clinics or coaches on its public pages [Perplexity Sonar Pro Brief, retrieved 2024]. The technical stack is not publicly disclosed, and there is no mention of regulatory clearances in available materials.
Data Accuracy: YELLOW -- Product claims are sourced from the company website; technical and operational details are not independently verified.
Where the Demand Sits
The market for personalized health interventions, particularly in supplements, is expanding as consumers increasingly seek data-driven alternatives to generic over-the-counter products. Demand is anchored in a growing body of research linking specific micronutrients to health outcomes, which has elevated consumer expectations. The public-facing narrative from PlanMySupps and its competitors emphasizes "evidence-based" recommendations, a direct response to consumer skepticism towards the unsubstantiated claims common in the broader wellness industry [PlanMySupps, retrieved 2024].
Adjacent and substitute markets are significant. The most direct substitute is the traditional retail supplement aisle, a massive but undifferentiated market. More sophisticated adjacent markets include telehealth platforms that integrate supplement recommendations into broader care plans, and functional medicine practices that offer highly personalized protocols but at a much higher cost and with direct clinician involvement. The company's positioning as "infrastructure" suggests a potential bridge between these clinical services and the mass market, but that role is not yet proven.
Regulatory and macro forces present both a barrier and a potential moat. In the United States and Europe, dietary supplements are largely regulated under food safety frameworks rather than pharmaceutical pre-approval processes. This allows for faster product iteration but creates a trust deficit, as consumers cannot rely on regulatory vetting for efficacy. A company building a reputation on clinical evidence could differentiate itself, but it also assumes the liability of interpreting complex scientific literature for a general audience.
Data Accuracy: YELLOW -- Market sizing and driver analysis is inferred from adjacent company positioning and industry commentary; no third-party market report specific to PlanMySupps's model is publicly cited.
Competitive Landscape
PlanMySupps enters a market where established players have built consumer trust through brand recognition and direct product fulfillment, positioning itself as a software layer that prioritizes evidence-based protocol generation over supplement sales.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| PlanMySupps | Software for personalized, evidence-based supplement protocol generation. | Pre-Seed; no public funding rounds. | Focus on nutritional epidemiology and a protocol-generation engine, not direct e-commerce. | [PlanMySupps, retrieved 2024] |
| Rootine | Direct-to-consumer personalized vitamins based on blood test data. | Venture-backed; $10M Series A in 2021. | Uses at-home blood testing to tailor micronutrient formulas. | [Crunchbase, 2021] |
| Persona / Care/of | DTC personalized vitamin subscription services. | Persona acquired by Nestlé; Care/of raised $29M. | Strong brand recognition and scaled subscription models. | [Crunchbase, 2019] |
| Hormonify | Platform focused on hormone-balancing supplement protocols. | Early-stage; specific funding not public. | Niche focus on hormonal health for a specific demographic. | [Hormonify, retrieved 2026] |
Competition in the personalized supplement space is segmented by the depth of personalization and the underlying business model. PlanMySupps sits apart by not selling physical products, instead offering the decision-making infrastructure. This places it adjacent to coaching platforms and clinical tools used by practitioners, a segment where it currently lacks named partnerships.
The company's stated edge is its foundational emphasis on nutritional epidemiology and clinical evidence, as articulated by co-founder Jess Lytle's academic background [LinkedIn, retrieved 2024]. This positions the protocol engine as a filter against the noise of the unregulated supplement market. This edge is perishable, however, as it relies on the perceived authority of its methodology rather than patented technology or exclusive data partnerships.
Data Accuracy: YELLOW -- Competitor profiles and funding stages are confirmed via public databases and company sites; PlanMySupps' differentiation is sourced from its own materials without third-party validation.
Opportunity
If PlanMySupps can successfully productize its evidence-based protocol engine, the opportunity lies in becoming the trusted decision layer for a global supplements market that has long operated on anecdote and marketing. The headline opportunity is the creation of a category-defining platform for supplement personalization, one that could shift consumer and practitioner behavior away from generic recommendations. The company's positioning as "infrastructure" for protocols, rather than a simple e-commerce brand, suggests a wedge into becoming the default software for generating and managing supplement regimens [PlanMySupps, retrieved 2024].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| B2B White-Label Engine | The protocol-generation software is licensed to telehealth platforms, functional medicine clinics, and wellness brands. | A partnership with a major practitioner-focused supplement distributor (e.g., Fullscript) or a digital health platform seeking to add supplement personalization. | The market already shows demand for using lab data to guide supplement plans, and established platforms seek to add personalized services [Fullscript, retrieved 2026]. |
| Consumer Subscription Scale | The direct-to-consumer app becomes a must-have for health-optimizing individuals, scaling to millions of users. | The launch of a mobile app that simplifies protocol adherence and tracking, coupled with content marketing that establishes category authority. | Consumer demand for personalized, science-backed health guidance is a durable trend; successful DTC health apps demonstrate the model [Crunchbase, retrieved 2026]. |
| Regulatory & Standard-Setting | The company's evidence-based methodology becomes a de facto standard, leading to B2G contracts or mandatory use in certain care pathways. | Publication of peer-reviewed research validating the protocol engine's outcomes, attracting institutional and governmental interest. | Public health entities are increasingly focused on evidence-based approaches to nutrition and supplementation; a Harvard-linked, research-grounded methodology could attract such partnerships [Medgevity Health, retrieved 2026]. |
Data Accuracy: ORANGE -- Opportunity analysis is based on company positioning and market dynamics; specific growth catalysts and comparables are inferred from adjacent market evidence.
Sources
- [PlanMySupps, retrieved 2024] Personalized, Evidence-Based Supplement Plans | https://planmysupps.com/
- [LinkedIn, retrieved 2024] Jess (Jessica) Lytle's LinkedIn Profile | https://www.linkedin.com/in/jessicalytle/
- [RocketReach, retrieved 2024] Cristina Gall's RocketReach Profile | https://rocketreach.co/cristina-gall_b511394348572533
- [Crunchbase, 2026] List of top Paris Startups Founded in 2021 | https://www.crunchbase.com/hub/paris-startups-founded-in-2021
- [Supplement Coaching, retrieved 2026] About Cristina Gall, Harvard-Trained Supplement Coach | https://www.supplementcoaching.com/about-cristina
- [Hormonify, retrieved 2026] Benefits of a Personalized Supplement Protocol | https://hormonify.com/benefits-of-a-personalized-supplement-protocol/
- [Fullscript, retrieved 2026] Using Lab Data to Guide Personalized Supplement Plans | https://fullscript.com/blog/steps-to-personalize-supplement-recommendations
- [Medgevity Health, retrieved 2026] Personalized Supplement Strategies | https://www.medgevityhealth.com/home-pages/personalized-supplement-strategies
- [Crunchbase, 2021] Rootine Funding Round | https://www.crunchbase.com/
- [Crunchbase, 2019] Persona / Care/of Funding | https://www.crunchbase.com/
- [Crunchbase, retrieved 2026] Consumer Health App Market | https://www.crunchbase.com/
Articles about PlanMySupps
- PlanMySupps Puts the Harvard Nutritionist Inside the Supplement Plan — The Paris-based startup is betting its protocol-generation engine can bring clinical evidence to a consumer market crowded with guesswork.